Measurement of serum p53 protein in patients with small cell lung cancer and results of its clinicopathological evaluation

Yoshihiko Segawa, Nagio Takigawa, Koichi Mandai, Yoshinobu Maeda, Ichiro Takata, Nobukazu Fujimoto, Kenji Jinno

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Serum p53 protein levels were measured in 36 patients with small cell lung cancer (SCLC) and 35 patients with benign lung diseases in order to evaluate the relationship of these levels to clinicopathological features of SCLC. Serum levels of p53 protein were measured by an enzyme-linked immunosorbent assay. p53 protein level was 23.92 ± 6.78 pg/ml in patients with SCLC, and similar to that (17.47 ± 2.86 pg/ml) in patients with benign lung diseases. By the clinical stage of SCLC, the mean level of p53 protein was 16.68 ± 4.62 pg/ml in 21 patients with limited disease, and lower than that in 15 patients with extensive disease (34.05 ± 14.84 pg/ml)(P = 0.23). The levels of p53 protein were not correlated with age, smoking index, or presence of cancer history for patients with SCLC. However, immunohistochemical examination disclosed a mild correlation between the expression of p53 protein by SCLC tumor and p53 protein serum level (r = 0.45, P = 0.02). Two patients with SCLC had an elevated serum level of p53 protein (> 2 S.D. above the mean for benign lung diseases). However, measurement of p53 protein serum level was not found to be clinically useful for detection of SCLC.

Original languageEnglish
Pages (from-to)229-238
Number of pages10
JournalLung Cancer
Volume16
Issue number2-3
DOIs
Publication statusPublished - Mar 1997
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Blood Proteins
Lung Diseases
Proteins
Serum
Neoplasms
Smoking
Enzyme-Linked Immunosorbent Assay

Keywords

  • enzyme-linked immunosorbent assay
  • immunohistochemistry
  • lung cancer
  • p53 gene
  • serum p53 protein
  • small cell lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Measurement of serum p53 protein in patients with small cell lung cancer and results of its clinicopathological evaluation. / Segawa, Yoshihiko; Takigawa, Nagio; Mandai, Koichi; Maeda, Yoshinobu; Takata, Ichiro; Fujimoto, Nobukazu; Jinno, Kenji.

In: Lung Cancer, Vol. 16, No. 2-3, 03.1997, p. 229-238.

Research output: Contribution to journalArticle

Segawa, Yoshihiko ; Takigawa, Nagio ; Mandai, Koichi ; Maeda, Yoshinobu ; Takata, Ichiro ; Fujimoto, Nobukazu ; Jinno, Kenji. / Measurement of serum p53 protein in patients with small cell lung cancer and results of its clinicopathological evaluation. In: Lung Cancer. 1997 ; Vol. 16, No. 2-3. pp. 229-238.
@article{e530826e5a23420e81c46e64783afc44,
title = "Measurement of serum p53 protein in patients with small cell lung cancer and results of its clinicopathological evaluation",
abstract = "Serum p53 protein levels were measured in 36 patients with small cell lung cancer (SCLC) and 35 patients with benign lung diseases in order to evaluate the relationship of these levels to clinicopathological features of SCLC. Serum levels of p53 protein were measured by an enzyme-linked immunosorbent assay. p53 protein level was 23.92 ± 6.78 pg/ml in patients with SCLC, and similar to that (17.47 ± 2.86 pg/ml) in patients with benign lung diseases. By the clinical stage of SCLC, the mean level of p53 protein was 16.68 ± 4.62 pg/ml in 21 patients with limited disease, and lower than that in 15 patients with extensive disease (34.05 ± 14.84 pg/ml)(P = 0.23). The levels of p53 protein were not correlated with age, smoking index, or presence of cancer history for patients with SCLC. However, immunohistochemical examination disclosed a mild correlation between the expression of p53 protein by SCLC tumor and p53 protein serum level (r = 0.45, P = 0.02). Two patients with SCLC had an elevated serum level of p53 protein (> 2 S.D. above the mean for benign lung diseases). However, measurement of p53 protein serum level was not found to be clinically useful for detection of SCLC.",
keywords = "enzyme-linked immunosorbent assay, immunohistochemistry, lung cancer, p53 gene, serum p53 protein, small cell lung cancer",
author = "Yoshihiko Segawa and Nagio Takigawa and Koichi Mandai and Yoshinobu Maeda and Ichiro Takata and Nobukazu Fujimoto and Kenji Jinno",
year = "1997",
month = "3",
doi = "10.1016/S0169-5002(97)82785-7",
language = "English",
volume = "16",
pages = "229--238",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2-3",

}

TY - JOUR

T1 - Measurement of serum p53 protein in patients with small cell lung cancer and results of its clinicopathological evaluation

AU - Segawa, Yoshihiko

AU - Takigawa, Nagio

AU - Mandai, Koichi

AU - Maeda, Yoshinobu

AU - Takata, Ichiro

AU - Fujimoto, Nobukazu

AU - Jinno, Kenji

PY - 1997/3

Y1 - 1997/3

N2 - Serum p53 protein levels were measured in 36 patients with small cell lung cancer (SCLC) and 35 patients with benign lung diseases in order to evaluate the relationship of these levels to clinicopathological features of SCLC. Serum levels of p53 protein were measured by an enzyme-linked immunosorbent assay. p53 protein level was 23.92 ± 6.78 pg/ml in patients with SCLC, and similar to that (17.47 ± 2.86 pg/ml) in patients with benign lung diseases. By the clinical stage of SCLC, the mean level of p53 protein was 16.68 ± 4.62 pg/ml in 21 patients with limited disease, and lower than that in 15 patients with extensive disease (34.05 ± 14.84 pg/ml)(P = 0.23). The levels of p53 protein were not correlated with age, smoking index, or presence of cancer history for patients with SCLC. However, immunohistochemical examination disclosed a mild correlation between the expression of p53 protein by SCLC tumor and p53 protein serum level (r = 0.45, P = 0.02). Two patients with SCLC had an elevated serum level of p53 protein (> 2 S.D. above the mean for benign lung diseases). However, measurement of p53 protein serum level was not found to be clinically useful for detection of SCLC.

AB - Serum p53 protein levels were measured in 36 patients with small cell lung cancer (SCLC) and 35 patients with benign lung diseases in order to evaluate the relationship of these levels to clinicopathological features of SCLC. Serum levels of p53 protein were measured by an enzyme-linked immunosorbent assay. p53 protein level was 23.92 ± 6.78 pg/ml in patients with SCLC, and similar to that (17.47 ± 2.86 pg/ml) in patients with benign lung diseases. By the clinical stage of SCLC, the mean level of p53 protein was 16.68 ± 4.62 pg/ml in 21 patients with limited disease, and lower than that in 15 patients with extensive disease (34.05 ± 14.84 pg/ml)(P = 0.23). The levels of p53 protein were not correlated with age, smoking index, or presence of cancer history for patients with SCLC. However, immunohistochemical examination disclosed a mild correlation between the expression of p53 protein by SCLC tumor and p53 protein serum level (r = 0.45, P = 0.02). Two patients with SCLC had an elevated serum level of p53 protein (> 2 S.D. above the mean for benign lung diseases). However, measurement of p53 protein serum level was not found to be clinically useful for detection of SCLC.

KW - enzyme-linked immunosorbent assay

KW - immunohistochemistry

KW - lung cancer

KW - p53 gene

KW - serum p53 protein

KW - small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0030975812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030975812&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(97)82785-7

DO - 10.1016/S0169-5002(97)82785-7

M3 - Article

C2 - 9152954

AN - SCOPUS:0030975812

VL - 16

SP - 229

EP - 238

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2-3

ER -